Background: Gestational diabetes mellitus (GDM) is carbohydrate intolerance first recognised throughout being pregnant and related to problems for moms and infants. Probiotics are naturally occurring micro-organisms, which when ingested in satisfactory quantities, could confer well being advantages. Proof of the function of probiotics as therapy for GDM is proscribed.

Goals: To guage the security and effectiveness of probiotics in treating girls with GDM on maternal and toddler outcomes.

Search strategies: We searched the Cochrane Being pregnant and Childbirth’s Trials Register ClinicalTrials.gov, WHO Worldwide Scientific Trials Registry Platform (ICTRP) (24 July 2019), and reference lists of retrieved research.

Choice standards: Randomised managed trials (RCTs) evaluating using probiotics versus placebo/commonplace take care of the therapy of GDM.

Information assortment and evaluation: Two overview authors independently assessed research eligibility, extracted knowledge, checked knowledge accuracy, and assessed danger of bias of included trials. The knowledge of proof for chosen maternal and toddler/baby outcomes was assessed utilizing GRADE.

Foremost outcomes: 9 RCTs (695 pregnant girls with GDM) evaluating probiotics versus placebo had been recognized. The general danger of bias within the 9 RCTs was low to unclear and the proof was downgraded for imprecision as a result of small numbers of ladies taking part within the trials. The trials had been carried out in hospitals and universities in Iran (seven trials), Thailand (one trial) and Eire (one trial). All trials in contrast probiotics with placebo. Maternal outcomes We’re unsure if probiotics have any impact in contrast with placebo on hypertensive problems of being pregnant, (danger ratio (RR) 1.50, 95% confidence interval (CI) 0.64 to three.53; individuals = 256; research = 3; low-certainty proof) and mode of beginning as caesareans (common RR 0.64, 95% CI 0.30 to 1.35; individuals = 267; research = 3; low-certainty proof) as a result of the knowledge of proof is low and the 95% CIs span potential profit and potential hurt. No trials reported major outcomes of: mode of beginning as vaginal/assisted and subsequent improvement of sort 2 diabetes. We’re unsure if probiotics have any impact in contrast with placebo on induction of labour (RR 1.33, 95% CI 0.74 to 2.37; individuals = 127; research = 1; very low-certainty proof). For different secondary maternal outcomes, we’re unsure if there are variations between probiotics and placebo for: postpartum haemorrhage; weight acquire throughout being pregnant intervention and whole gestational weight acquire; fasting plasma glucose and want for further pharmacotherapy (insulin). Probiotics could also be related to a slight discount in triglycerides and whole ldl cholesterol.

In probiotics in contrast with placebo, there was proof of discount in markers for insulin resistance (HOMA-IR) and HOMA-B; and insulin secretion. There was additionally a rise in quantitative insulin sensitivity test index (QUICKI). Probiotics had been related to minor advantages in related bio-markers with proof of a discount in inflammatory markers high-sensitivity C-reactive protein (hs-CRP), interleukin 6 (IL-6), and marker of oxidative stress malondialdehyde; and a rise in antioxidant whole glutathione, however we’re unsure if there may be any distinction in whole antioxidant capability. No trials reported secondary outcomes: perineal trauma, postnatal weight retention or return to pre-pregnancy weight and postnatal melancholy.

Toddler/baby/grownup outcomes We’re unsure if probiotics have any impact, in contrast with placebo, on the danger of large-for-gestational-age infants (RR 0.73, 95% CI 0.35 to 1.52; individuals = 174; research = 2; low-certainty proof) or toddler hypoglycaemia (RR 0.85, 95% CI 0.39 to 1.84; individuals = 177; research = 3; low-certainty proof) as a result of the knowledge of proof is low and the 95% CIs span potential profit and potential hurt. No trials reported major outcomes of: perinatal (fetal/neonatal) mortality; or neurosensory incapacity. For different secondary outcomes, we’re unsure if there may be any distinction between probiotics and placebo in gestational age at beginning, preterm beginning, macrosomia, birthweight, head circumference, size, toddler hypoglycaemia, and neonatal intensive care unit (NICU) admissions. There was proof of a discount in toddler hyperbilirubinaemia with probiotics in contrast with placebo. No trials reported secondary outcomes: toddler adiposity, and later childhood adiposity. There have been no adversarial occasions reported by any of the trials.

Authors’ conclusions: Low-certainty proof means we’re not sure if there may be any distinction between probiotic and placebo teams in maternal hypertensive problems of being pregnant, caesareans; and large-for-gestational-age infants. There have been no adversarial occasions reported by the trials. Because of the variability of probiotics used and small pattern sizes of trials, proof from this overview has restricted means to tell observe. Nicely-designed adequately-powered trials are wanted to establish whether or not probiotics could enhance maternal blood glucose ranges and/or toddler/baby/grownup outcomes; and whether or not they can be utilized to deal with GDM.

Environmental danger evaluation related to aquatic and terrestrial contamination is usually based mostly on predicted or measured environmental concentrations of a restricted checklist of chemical substances in a restricted variety of environmental compartments. Excessive decision mass spectrometry (HRMS) can present a extra complete image of publicity to dangerous chemical substances, significantly by means of the retrospective evaluation of digitally saved HRMS knowledge. Utilizing this technique, our research characterised the contamination of varied environmental compartments together with 154 floor water, 46 city effluent, 67 sediment, 15 soil, 34 groundwater, 24 biomovie, 41 gammarid and 49 fish samples at 95 websites broadly distributed over the Swiss Plateau.

As a proof-of-concept, we targeted our investigation on antifungal azoles, a category of chemical substances of rising concern on account of their endocrine disrupting results on aquatic organisms and people. Our outcomes demonstrated the prevalence of antifungal azoles and a few of their (bio)transformation merchandise in all of the analyzed compartments (0.1-100 ng/L or ng/g d.w.). Comparability of precise and predicted concentrations confirmed the partial suitability of degree 1 fugacity modelling in predicting the publicity to azoles. Danger quotient calculations moreover revealed danger of publicity particularly if a number of the investigated rivers and streams are used for consuming water manufacturing.

F5(Coagulation factor V light chain) Antibody
47757	SAB	100ul	EUR 319

F5(Coagulation factor V light chain) Antibody
47757-100ul	SAB	100ul	EUR 302.4

F5 (Coagulation factor V light chain) Antibody
E047757	EnoGene	100μg/100μl	EUR 255
Description: Available in various conjugation types.

Factor XI light chain Antibody HRP Conjugated
MBS9461967-01mL	MyBiosource	0.1mL	EUR 595

Factor XI light chain Antibody HRP Conjugated
MBS9461967-5x01mL	MyBiosource	5x0.1mL	EUR 2525

F5 (Coagulation factor V light chain) Antibody
MBS9430739-01mL	MyBiosource	0.1mL	EUR 305

F5 (Coagulation factor V light chain) Antibody
MBS9430739-5x01mL	MyBiosource	5x0.1mL	EUR 1230

Factor XII Light Chain Monoclonal Antibody
MBS190156-025mg	MyBiosource	0.25mg	EUR 585

Factor XII Light Chain Monoclonal Antibody
MBS190156-5x025mg	MyBiosource	5x0.25mg	EUR 2630

Factor VIIIa light chain Antibody HRP Conjugated
MBS9460247-01mL	MyBiosource	0.1mL	EUR 595

Factor VIIIa light chain Antibody HRP Conjugated
MBS9460247-5x01mL	MyBiosource	5x0.1mL	EUR 2525

OAMA01543-250UG - Factor XII Light Chain Antibody
OAMA01543-250UG	Aviva Systems Biology	0.25MG	EUR 1049

F5(Coagulation factor V light chain) Conjugated Antibody
C47757	SAB	100ul	EUR 476.4

F5 (Coagulation Factor V Light Chain) Conjugated Antibody
MBS9455604-01mLAF350	MyBiosource	0.1mL(AF350)	EUR 480

F5 (Coagulation Factor V Light Chain) Conjugated Antibody
MBS9455604-01mLAF405	MyBiosource	0.1mL(AF405)	EUR 480

F5 (Coagulation Factor V Light Chain) Conjugated Antibody
MBS9455604-01mLAF488	MyBiosource	0.1mL(AF488)	EUR 480

F5 (Coagulation Factor V Light Chain) Conjugated Antibody
MBS9455604-01mLAF555	MyBiosource	0.1mL(AF555)	EUR 480

F5 (Coagulation Factor V Light Chain) Conjugated Antibody
MBS9455604-01mLBiotin	MyBiosource	0.1mL(Biotin)	EUR 480

Factor VII light chain Polyclonal Antibody FITC Conjugated
MBS9463995-01mL	MyBiosource	0.1mL	EUR 595

Factor VII light chain Polyclonal Antibody FITC Conjugated
MBS9463995-5x01mL	MyBiosource	5x0.1mL	EUR 2525

Human Factor X Light Chain AssayLite Antibody (FITC Conjugate)
72215-05141	AssayPro	150 ug	EUR 513.6

Factor VIIIa light chain
E8ER1908-48	EnoGene	100ul	EUR 275
Description: Available in various conjugation types.

Factor VIIIa light chain
MBS8577540-01mL	MyBiosource	0.1mL	EUR 345

Factor VIIIa light chain
MBS8577540-01mLAF405L	MyBiosource	0.1mL(AF405L)	EUR 565

Factor VIIIa light chain
MBS8577540-01mLAF405S	MyBiosource	0.1mL(AF405S)	EUR 565

Factor VIIIa light chain
MBS8577540-01mLAF610	MyBiosource	0.1mL(AF610)	EUR 565

Factor VIIIa light chain
MBS8577540-01mLAF635	MyBiosource	0.1mL(AF635)	EUR 565

F5(Coagulation factor V light chain) Rabbit Polyclonal Antibody
E10G13377	EnoGene	100 μl	EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

Factor XII Light Chain (Hageman Factor)
MBS602874-025mg	MyBiosource	0.25mg	EUR 1630

Factor XII Light Chain (Hageman Factor)
MBS602874-5x025mg	MyBiosource	5x0.25mg	EUR 7190

MAb to Factor XII Light Chain
MBS311789-025mg	MyBiosource	0.25mg	EUR 1295

MAb to Factor XII Light Chain
MBS311789-5x025mg	MyBiosource	5x0.25mg	EUR 5655

Factor Va light chain, non-calcium
MBS603252-01mg	MyBiosource	0.1mg	EUR 395

Factor Va light chain, non-calcium
MBS603252-5x01mg	MyBiosource	5x0.1mg	EUR 1640

Factor XII (F12) (light chain) mouse monoclonal antibody, clone 802, Azide Free
BM2324	Origene Technologies GmbH	0.25 mg	Ask for price

Coagulation Factor X Cleaved-Ala41 Light Chain (F10 Cleaved-A41) Antibody
abx015573-1mg	Abbexa	1 mg	EUR 43.75

Factor Va, light chain, fragment E, 74kD
MBS604982-01mg	MyBiosource	0.1mg	EUR 410

Factor Va, light chain, fragment E, 74kD
MBS604982-5x01mg	MyBiosource	5x0.1mg	EUR 1700

Anti-Factor V Light Chain Antibody
19701	Genovis AB	250ug	EUR 538

Coagulation Factor VII Cleaved-Arg212 Light Chain (F7 Cleaved-R212) Antibody
abx015588-1mg	Abbexa	1 mg	EUR 43.75

Light chain Antibody
E043108	EnoGene	100μg/100μl	EUR 255
Description: Available in various conjugation types.

Anti-Factor XII Light Chain Antibody
19802	Genovis AB	250ug	EUR 538

Myosin Light Chain 2 (Myosin Light Chain 2) Antibody
20-abx137423	Abbexa	Ask for price Ask for price Ask for price	100 ug 20 ug 5 ug

Myosin Light Chain 2 (Myosin Light Chain 2) Antibody
abx235519-100ug	Abbexa	100 ug	EUR 577.2

Myosin Light Chain 2 (Myosin Light Chain 2) Antibody
abx235520-100ug	Abbexa	100 ug	EUR 610.8

Factor V, Va, light chain, fragment E, 74kD
MBS606278-01mg	MyBiosource	0.1mg	EUR 410

Factor V, Va, light chain, fragment E, 74kD
MBS606278-5x01mg	MyBiosource	5x0.1mg	EUR 1700

Factor Va, light chain, fragment E, 74kD (HRP)
MBS607208-005mg	MyBiosource	0.05mg	EUR 765

Factor Va, light chain, fragment E, 74kD (HRP)
MBS607208-5x005mg	MyBiosource	5x0.05mg	EUR 3300

IgG light chain Antibody
abx140241-01mg	Abbexa	0.1 mg	EUR 427.2

IgG Light chain Antibody
GWB-4802DD	GenWay Biotech	0.1 mg	Ask for price

IgG light chain Antibody
abx140241-100g	Abbexa	100 µg	EUR 275

CD98 Light Chain Antibody
GWB-61A3F5	GenWay Biotech	0.05 mg	Ask for price

kappa light chain Antibody
abx025345-400ul	Abbexa	400 ul	EUR 627.6

kappa light chain Antibody
abx025345-80l	Abbexa	80 µl	EUR 343.2

Kappa Light chain Antibody
46588	SAB	100ul	EUR 319

Kappa Light chain Antibody
46588-100ul	SAB	100ul	EUR 302.4

Kappa Light chain Antibody
E046588	EnoGene	100μg/100μl	EUR 255
Description: Available in various conjugation types.

Kappa light chain Antibody
DF13703	Affbiotech	100ul	EUR 420

Kappa light chain Antibody
DF13703-100ul	Affinity Biosciences	100ul	EUR 280

Kappa light chain Antibody
DF13703-200ul	Affinity Biosciences	200ul	EUR 350

kappa Light chain Antibody
GWB-4A08DD	GenWay Biotech	0.1 mg	Ask for price

kappa Light chain Antibody
GWB-547A76	GenWay Biotech	1 ml	Ask for price

Kappa Light Chain Antibody
GWB-5FEF2F	GenWay Biotech	10 ml	Ask for price

Kappa Light Chain Antibody
GWB-631D07	GenWay Biotech	1 ml	Ask for price

Kappa Light Chain Antibody
GWB-2AA0D3	GenWay Biotech	1 ml	Ask for price

kappa Light chain Antibody
GWB-2C9AA4	GenWay Biotech	10 ml	Ask for price

Kappa Light Chain Antibody
GWB-34756E	GenWay Biotech	1 ml	Ask for price

Kappa Light Chain Antibody
GWB-Q00552	GenWay Biotech	1 mg	Ask for price

Kappa Light Chain Antibody
GWB-809A80	GenWay Biotech	6 ml	Ask for price

kappa Light chain Antibody
GWB-8133FB	GenWay Biotech	0.5 mg	Ask for price

kappa Light chain Antibody
GWB-816139	GenWay Biotech	1 ml	Ask for price

Kappa Light Chain Antibody
GWB-9FD3EC	GenWay Biotech	10 ml	Ask for price

Kappa Light Chain Antibody
GWB-6A9A88	GenWay Biotech	0.5 mg	Ask for price

Kappa Light Chain Antibody
GWB-FD3072	GenWay Biotech	1 ml	Ask for price

Kappa Light Chain Antibody
GWB-E7B282	GenWay Biotech	0.5 mg	Ask for price

Kappa Light Chain Antibody
GWB-C01870	GenWay Biotech	1 mg	Ask for price

Kappa Light Chain Antibody
R20178-100UG	NSJ Bioreagents	100ug	EUR 347.65
Description: This recombinant Human Kappa Light Chain antibody reacts to the kappa light chain of human immunoglobulins. No cross reactivity with lambda or mouse/rat/goat IgG.

Kappa Light Chain Antibody
R20178BTN-50UG	NSJ Bioreagents	50ug	EUR 347.65
Description: This recombinant Human Kappa Light Chain antibody reacts to the kappa light chain of human immunoglobulins. No cross reactivity with the lambda light chain, mouse IgG, rat IgG, or goat IgG.

Kappa Light Chain Antibody
R20178SAF-250UG	NSJ Bioreagents	250ug	EUR 832.15
Description: This recombinant Human Kappa Light Chain antibody reacts to the kappa light chain of human immunoglobulins. No cross reactivity with lambda or mouse/rat/goat IgG.

Kappa Light Chain Antibody
RQ5072	NSJ Bioreagents	100ul	EUR 356.15
Description: The immunoglobulin light chain is the small polypeptide subunit of an antibody (immunoglobulin). A typical antibody is composed of two immunoglobulin (Ig) heavy chains and two Ig light chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. [Wiki]

kappa light chain Antibody
abx025345-400l	Abbexa	400 µl	EUR 518.75

Kappa Light Chain Antibody
V9030-100UG	NSJ Bioreagents	100 ug	EUR 424.15
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of kappa to lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V9030-20UG	NSJ Bioreagents	20 ug	EUR 186.15
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of kappa to lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V9030IHC-7ML	NSJ Bioreagents	7 ml	EUR 424.15
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of kappa to lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V9030SAF-100UG	NSJ Bioreagents	100 ug	EUR 424.15
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of kappa to lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V9031-100UG	NSJ Bioreagents	100 ug	EUR 424.15
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V9031-20UG	NSJ Bioreagents	20 ug	EUR 186.15
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V9031IHC-7ML	NSJ Bioreagents	7 ml	EUR 424.15
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V9031SAF-100UG	NSJ Bioreagents	100 ug	EUR 424.15
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3681-100UG	NSJ Bioreagents	100 ug	EUR 424.15
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3681-20UG	NSJ Bioreagents	20 ug	EUR 186.15
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3681IHC-7ML	NSJ Bioreagents	7 ml	EUR 424.15
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3681SAF-100UG	NSJ Bioreagents	100 ug	EUR 424.15
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3713-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3713-20UG	NSJ Bioreagents	20 ug	EUR 153.3
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3713IHC-7ML	NSJ Bioreagents	7 ml	EUR 349.3
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3713SAF-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3846-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3846-20UG	NSJ Bioreagents	20 ug	EUR 153.3
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3846SAF-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3855-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3855-20UG	NSJ Bioreagents	20 ug	EUR 153.3
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3855SAF-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V7052-100UG	NSJ Bioreagents	100 ug	EUR 424.15
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V7052-20UG	NSJ Bioreagents	20 ug	EUR 186.15
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V7052IHC-7ML	NSJ Bioreagents	7 ml	EUR 424.15
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V7052SAF-100UG	NSJ Bioreagents	100 ug	EUR 424.15
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3135-100UG	NSJ Bioreagents	100 ug	EUR 424.15
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. It recognizes human Ig kappa light chains of both secreted and cell surface immunoglobulin. It detects also free kappa light chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3135-20UG	NSJ Bioreagents	20 ug	EUR 186.15
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. It recognizes human Ig kappa light chains of both secreted and cell surface immunoglobulin. It detects also free kappa light chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3135IHC-7ML	NSJ Bioreagents	7 ml	EUR 424.15
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. It recognizes human Ig kappa light chains of both secreted and cell surface immunoglobulin. It detects also free kappa light chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3135SAF-100UG	NSJ Bioreagents	100 ug	EUR 424.15
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. It recognizes human Ig kappa light chains of both secreted and cell surface immunoglobulin. It detects also free kappa light chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3148-100UG	NSJ Bioreagents	100 ug	EUR 424.15
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3148-20UG	NSJ Bioreagents	20 ug	EUR 186.15
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3148IHC-7ML	NSJ Bioreagents	7 ml	EUR 424.15
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3148SAF-100UG	NSJ Bioreagents	100 ug	EUR 424.15
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3302-100UG	NSJ Bioreagents	100 ug	EUR 424.15
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3302-20UG	NSJ Bioreagents	20 ug	EUR 186.15
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3302SAF-100UG	NSJ Bioreagents	100 ug	EUR 424.15
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3591-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3591-20UG	NSJ Bioreagents	20 ug	EUR 153.3
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3591IHC-7ML	NSJ Bioreagents	7 ml	EUR 349.3
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3591SAF-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3592-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3592-20UG	NSJ Bioreagents	20 ug	EUR 153.3
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3592IHC-7ML	NSJ Bioreagents	7 ml	EUR 349.3
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3592SAF-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3606-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3606-20UG	NSJ Bioreagents	20 ug	EUR 153.3
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3606IHC-7ML	NSJ Bioreagents	7 ml	EUR 349.3
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V3606SAF-100UG	NSJ Bioreagents	100 ug	EUR 349.3
Description: This mAb is specific to kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Kappa Light Chain Antibody
V2145-100UG	NSJ Bioreagents	100 ug	EUR 424.15
Description: This antibody is specific to the kappa light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general, the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the kappa light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

The case research clearly reveals that the retrospective evaluation of HRMS/MS knowledge can enhance the present information on publicity and the associated dangers to chemical substances of rising concern and may be successfully employed sooner or later for such functions. Innovation diffusion principle proposed that adopters-whether people or organizations-sometimes reinvent an innovation as they acquire expertise utilizing it. Reinvention can improve (or impede) the probability of an IS innovation’s acceptance and additional diffusion. This paper stories on a case research of BioSense, an interorganizational system that was designed as an early detection software for bio-terror assaults and subsequently modified to raised serve this want in addition to to function as a public well being system for pinpointing geographic clusters of harmful/acute illness outbreaks. By inspecting the interaction among the many political and organizational dynamics and technical properties of the BioSense system, we make clear processes affecting reinvention in an interorganizational context.